Mario Santiago
Concepts (399)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Friend murine leukemia virus | 17 | 2021 | 29 | 6.160 |
Why?
| Retroviridae Infections | 21 | 2024 | 46 | 5.590 |
Why?
| Cytidine Deaminase | 21 | 2024 | 57 | 5.400 |
Why?
| HIV-1 | 30 | 2024 | 836 | 3.310 |
Why?
| Virus Replication | 19 | 2024 | 444 | 2.560 |
Why?
| Antibodies, Neutralizing | 10 | 2022 | 263 | 2.480 |
Why?
| HIV Infections | 22 | 2024 | 2701 | 1.940 |
Why?
| Simian Immunodeficiency Virus | 19 | 2015 | 83 | 1.930 |
Why?
| Interferon-alpha | 7 | 2020 | 192 | 1.910 |
Why?
| Antiviral Agents | 9 | 2022 | 703 | 1.900 |
Why?
| Antibodies, Viral | 12 | 2022 | 601 | 1.770 |
Why?
| Somatic Hypermutation, Immunoglobulin | 3 | 2022 | 19 | 1.730 |
Why?
| Simian Acquired Immunodeficiency Syndrome | 11 | 2015 | 80 | 1.600 |
Why?
| Antigens, CD | 5 | 2016 | 482 | 1.550 |
Why?
| Tumor Virus Infections | 8 | 2024 | 45 | 1.490 |
Why?
| Dendritic Cells | 5 | 2020 | 479 | 1.400 |
Why?
| Gastrointestinal Tract | 3 | 2022 | 182 | 1.380 |
Why?
| Adaptive Immunity | 3 | 2021 | 157 | 1.230 |
Why?
| Immunity, Innate | 12 | 2024 | 802 | 1.200 |
Why?
| Membrane Glycoproteins | 3 | 2016 | 466 | 1.120 |
Why?
| Interferon Type I | 7 | 2022 | 140 | 1.110 |
Why?
| CD4-Positive T-Lymphocytes | 11 | 2022 | 1046 | 0.970 |
Why?
| Interferons | 3 | 2024 | 192 | 0.940 |
Why?
| Pan troglodytes | 11 | 2009 | 58 | 0.920 |
Why?
| SAM Domain and HD Domain-Containing Protein 1 | 2 | 2021 | 10 | 0.910 |
Why?
| Mice, Inbred BALB C | 11 | 2024 | 1228 | 0.810 |
Why?
| Animals | 63 | 2025 | 34479 | 0.750 |
Why?
| Immunoglobulin A | 2 | 2022 | 201 | 0.750 |
Why?
| Mice, Knockout | 13 | 2024 | 2755 | 0.750 |
Why?
| Interferon-beta | 2 | 2020 | 87 | 0.720 |
Why?
| Viral Load | 9 | 2021 | 450 | 0.680 |
Why?
| B-Lymphocytes | 6 | 2023 | 817 | 0.680 |
Why?
| Virion | 4 | 2016 | 83 | 0.650 |
Why?
| Mice | 28 | 2025 | 16602 | 0.650 |
Why?
| Proteins | 6 | 2022 | 932 | 0.630 |
Why?
| CD8-Positive T-Lymphocytes | 8 | 2021 | 846 | 0.630 |
Why?
| Killer Cells, Natural | 5 | 2016 | 426 | 0.610 |
Why?
| Mice, Inbred C57BL | 17 | 2025 | 5272 | 0.600 |
Why?
| Leukemia, Experimental | 4 | 2014 | 27 | 0.600 |
Why?
| Endogenous Retroviruses | 2 | 2024 | 34 | 0.590 |
Why?
| Lipopolysaccharides | 1 | 2021 | 856 | 0.590 |
Why?
| RNA, Viral | 9 | 2024 | 616 | 0.560 |
Why?
| Enterobacteriaceae | 1 | 2017 | 35 | 0.540 |
Why?
| Host-Pathogen Interactions | 5 | 2024 | 346 | 0.540 |
Why?
| Receptor, Interferon alpha-beta | 3 | 2024 | 33 | 0.540 |
Why?
| Immunity, Cellular | 2 | 2016 | 263 | 0.500 |
Why?
| Immunoglobulin Variable Region | 1 | 2015 | 79 | 0.480 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2015 | 80 | 0.480 |
Why?
| Immunomodulation | 1 | 2016 | 89 | 0.480 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2015 | 40 | 0.460 |
Why?
| Feces | 10 | 2017 | 435 | 0.460 |
Why?
| Dysbiosis | 4 | 2022 | 166 | 0.450 |
Why?
| Viremia | 6 | 2020 | 130 | 0.450 |
Why?
| Signal Transduction | 6 | 2024 | 4826 | 0.440 |
Why?
| Intestines | 1 | 2017 | 344 | 0.440 |
Why?
| Virus Diseases | 3 | 2022 | 209 | 0.410 |
Why?
| Endoribonucleases | 1 | 2013 | 70 | 0.410 |
Why?
| Antibody Formation | 3 | 2017 | 288 | 0.400 |
Why?
| Colon | 5 | 2024 | 248 | 0.390 |
Why?
| Molecular Sequence Data | 15 | 2014 | 2819 | 0.370 |
Why?
| Antibody Affinity | 1 | 2010 | 59 | 0.340 |
Why?
| HIV Seropositivity | 2 | 2022 | 119 | 0.330 |
Why?
| Spleen | 5 | 2018 | 507 | 0.330 |
Why?
| Retroviridae | 3 | 2023 | 97 | 0.330 |
Why?
| Intestinal Mucosa | 4 | 2019 | 575 | 0.330 |
Why?
| Antigens, Helminth | 2 | 1999 | 12 | 0.330 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 940 | 0.320 |
Why?
| Cercocebus atys | 3 | 2006 | 6 | 0.320 |
Why?
| Humans | 60 | 2024 | 128418 | 0.320 |
Why?
| HIV-2 | 3 | 2006 | 18 | 0.310 |
Why?
| Schistosomiasis japonica | 2 | 1999 | 32 | 0.310 |
Why?
| Animals, Wild | 3 | 2005 | 50 | 0.310 |
Why?
| Base Sequence | 7 | 2015 | 2135 | 0.310 |
Why?
| Cells, Cultured | 10 | 2018 | 4001 | 0.300 |
Why?
| Macaca mulatta | 5 | 2021 | 146 | 0.300 |
Why?
| Interleukin-15 | 2 | 2021 | 82 | 0.300 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2016 | 2062 | 0.300 |
Why?
| Lymphocytes | 2 | 2021 | 367 | 0.290 |
Why?
| Lymphocyte Activation | 5 | 2017 | 1098 | 0.290 |
Why?
| Antigen Presentation | 2 | 2021 | 205 | 0.290 |
Why?
| Reverse Transcription | 2 | 2021 | 18 | 0.290 |
Why?
| Ape Diseases | 3 | 2008 | 7 | 0.290 |
Why?
| Gastrointestinal Microbiome | 5 | 2024 | 633 | 0.280 |
Why?
| Immunity, Humoral | 2 | 2022 | 117 | 0.280 |
Why?
| Gene Expression Profiling | 6 | 2024 | 1688 | 0.280 |
Why?
| Disease Reservoirs | 2 | 2006 | 19 | 0.280 |
Why?
| Flow Cytometry | 4 | 2017 | 1142 | 0.270 |
Why?
| Papillomavirus Infections | 2 | 2022 | 290 | 0.270 |
Why?
| Immunity, Mucosal | 3 | 2020 | 94 | 0.260 |
Why?
| Sequence Analysis, DNA | 5 | 2017 | 771 | 0.260 |
Why?
| Genetic Variation | 4 | 2015 | 933 | 0.240 |
Why?
| Phylogeny | 13 | 2017 | 838 | 0.240 |
Why?
| Immunoglobulin G | 4 | 2022 | 843 | 0.240 |
Why?
| Thymocytes | 1 | 2025 | 32 | 0.230 |
Why?
| Glycogen Synthase Kinase 3 beta | 1 | 2025 | 67 | 0.230 |
Why?
| Disease Models, Animal | 5 | 2018 | 3937 | 0.230 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2024 | 43 | 0.230 |
Why?
| Frameshifting, Ribosomal | 1 | 2024 | 6 | 0.230 |
Why?
| HIV Long Terminal Repeat | 1 | 2024 | 10 | 0.230 |
Why?
| Interferon-gamma | 2 | 2019 | 759 | 0.230 |
Why?
| Granzymes | 2 | 2022 | 46 | 0.230 |
Why?
| Bone Marrow Cells | 3 | 2016 | 294 | 0.230 |
Why?
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 108 | 0.230 |
Why?
| Cercopithecus | 1 | 2003 | 2 | 0.220 |
Why?
| Immunoglobulin M | 4 | 2022 | 272 | 0.220 |
Why?
| Alternative Splicing | 2 | 2024 | 217 | 0.220 |
Why?
| DNA Transposable Elements | 1 | 2024 | 118 | 0.220 |
Why?
| DNA, Viral | 3 | 2021 | 348 | 0.220 |
Why?
| Exons | 1 | 2024 | 338 | 0.210 |
Why?
| Transcriptome | 2 | 2022 | 881 | 0.210 |
Why?
| NF-kappa B | 2 | 2018 | 649 | 0.210 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2025 | 334 | 0.210 |
Why?
| Antibodies, Helminth | 2 | 1999 | 6 | 0.200 |
Why?
| Recombination, Genetic | 4 | 2015 | 189 | 0.200 |
Why?
| Genome, Viral | 1 | 2003 | 127 | 0.190 |
Why?
| RNA, Messenger | 3 | 2024 | 2675 | 0.190 |
Why?
| HEK293 Cells | 5 | 2024 | 683 | 0.190 |
Why?
| Viral Regulatory and Accessory Proteins | 2 | 2016 | 26 | 0.190 |
Why?
| Blood | 1 | 2022 | 99 | 0.190 |
Why?
| Ruminococcus | 1 | 2021 | 9 | 0.190 |
Why?
| Acute Disease | 2 | 2016 | 964 | 0.190 |
Why?
| Acinetobacter | 1 | 2021 | 13 | 0.190 |
Why?
| T-Lymphocytes, Helper-Inducer | 2 | 2023 | 136 | 0.180 |
Why?
| Peripheral Tolerance | 2 | 2020 | 15 | 0.180 |
Why?
| Male | 22 | 2024 | 62858 | 0.180 |
Why?
| Lymphopenia | 1 | 2021 | 59 | 0.180 |
Why?
| Female | 24 | 2024 | 68154 | 0.180 |
Why?
| Evolution, Molecular | 3 | 2016 | 463 | 0.180 |
Why?
| Specimen Handling | 1 | 2022 | 164 | 0.180 |
Why?
| Bacterial Translocation | 2 | 2019 | 38 | 0.170 |
Why?
| Interferon-Induced Helicase, IFIH1 | 1 | 2020 | 15 | 0.170 |
Why?
| Picornaviridae | 1 | 2020 | 17 | 0.170 |
Why?
| Tropomyosin | 1 | 1999 | 12 | 0.170 |
Why?
| Immunologic Factors | 2 | 2019 | 225 | 0.160 |
Why?
| Salmonella typhimurium | 1 | 2021 | 176 | 0.160 |
Why?
| Cell Line | 6 | 2020 | 2731 | 0.160 |
Why?
| Genotype | 3 | 2013 | 1828 | 0.160 |
Why?
| nef Gene Products, Human Immunodeficiency Virus | 3 | 2016 | 17 | 0.160 |
Why?
| Immunologic Memory | 1 | 2021 | 341 | 0.160 |
Why?
| Keratinocytes | 2 | 2018 | 243 | 0.160 |
Why?
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2018 | 4 | 0.160 |
Why?
| Helminth Proteins | 1 | 1999 | 19 | 0.160 |
Why?
| Lymph Nodes | 3 | 2018 | 466 | 0.160 |
Why?
| Interleukin-2 | 2 | 2022 | 434 | 0.160 |
Why?
| GPI-Linked Proteins | 2 | 2016 | 67 | 0.160 |
Why?
| Gram-Positive Bacteria | 1 | 2019 | 45 | 0.160 |
Why?
| Gram-Negative Bacteria | 1 | 2019 | 68 | 0.150 |
Why?
| Lectins | 1 | 2018 | 46 | 0.150 |
Why?
| Protective Agents | 1 | 2018 | 36 | 0.150 |
Why?
| Sexually Transmitted Diseases, Viral | 1 | 1998 | 8 | 0.150 |
Why?
| Papillomavirus E7 Proteins | 1 | 2018 | 10 | 0.150 |
Why?
| Cullin Proteins | 1 | 2018 | 13 | 0.150 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 2018 | 168 | 0.150 |
Why?
| HIV | 3 | 2018 | 225 | 0.150 |
Why?
| Human papillomavirus 16 | 1 | 2018 | 33 | 0.150 |
Why?
| Human Immunodeficiency Virus Proteins | 2 | 2016 | 6 | 0.140 |
Why?
| Proteome | 1 | 2022 | 430 | 0.140 |
Why?
| APOBEC-1 Deaminase | 2 | 2014 | 5 | 0.140 |
Why?
| Viral Tropism | 1 | 2017 | 28 | 0.140 |
Why?
| Proteolysis | 1 | 2018 | 162 | 0.140 |
Why?
| Interleukins | 1 | 2019 | 242 | 0.140 |
Why?
| Allergens | 1 | 2020 | 383 | 0.140 |
Why?
| Immunoglobulin E | 1 | 1999 | 329 | 0.140 |
Why?
| Parvoviridae Infections | 1 | 2016 | 11 | 0.130 |
Why?
| Toll-Like Receptor 7 | 1 | 2016 | 37 | 0.130 |
Why?
| Mutagenesis, Insertional | 1 | 2016 | 65 | 0.130 |
Why?
| Influenza, Human | 1 | 2022 | 601 | 0.130 |
Why?
| Disease Resistance | 1 | 2016 | 31 | 0.130 |
Why?
| Case-Control Studies | 2 | 2022 | 3328 | 0.130 |
Why?
| Butyrates | 1 | 2017 | 54 | 0.130 |
Why?
| Leukocytes, Mononuclear | 4 | 2024 | 539 | 0.130 |
Why?
| Interleukin-12 | 1 | 2016 | 119 | 0.130 |
Why?
| Amino Acid Sequence | 6 | 2016 | 2040 | 0.130 |
Why?
| Lymphoid Tissue | 2 | 2020 | 68 | 0.130 |
Why?
| Biological Products | 1 | 2019 | 197 | 0.130 |
Why?
| Primates | 2 | 2015 | 118 | 0.130 |
Why?
| B7-1 Antigen | 1 | 2016 | 58 | 0.130 |
Why?
| PTEN Phosphohydrolase | 1 | 2017 | 157 | 0.130 |
Why?
| NIH 3T3 Cells | 1 | 2016 | 141 | 0.120 |
Why?
| Gene Products, nef | 2 | 2006 | 9 | 0.120 |
Why?
| Antibody Diversity | 1 | 2015 | 16 | 0.120 |
Why?
| Phenotype | 2 | 2016 | 3044 | 0.120 |
Why?
| Histones | 1 | 2020 | 586 | 0.120 |
Why?
| Cell Proliferation | 2 | 2019 | 2344 | 0.120 |
Why?
| Toll-Like Receptor 3 | 1 | 2014 | 27 | 0.120 |
Why?
| Colobus | 1 | 2014 | 3 | 0.120 |
Why?
| Major Histocompatibility Complex | 1 | 2016 | 229 | 0.120 |
Why?
| Endocytosis | 1 | 2016 | 161 | 0.120 |
Why?
| Bacteria | 2 | 2022 | 808 | 0.120 |
Why?
| Neoplasms | 2 | 2022 | 2464 | 0.120 |
Why?
| Gene Expression Regulation | 4 | 2024 | 2505 | 0.120 |
Why?
| Autoimmunity | 1 | 2020 | 860 | 0.110 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2017 | 375 | 0.110 |
Why?
| Biological Evolution | 2 | 2012 | 424 | 0.110 |
Why?
| Cote d'Ivoire | 2 | 2005 | 9 | 0.110 |
Why?
| Cloning, Molecular | 3 | 2013 | 522 | 0.110 |
Why?
| Prevalence | 4 | 2006 | 2547 | 0.110 |
Why?
| Papillomaviridae | 1 | 2014 | 113 | 0.110 |
Why?
| env Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 15 | 0.110 |
Why?
| Germinal Center | 1 | 2014 | 57 | 0.110 |
Why?
| Gene Frequency | 1 | 2015 | 504 | 0.110 |
Why?
| APOBEC Deaminases | 2 | 2024 | 5 | 0.110 |
Why?
| Immunization | 2 | 2020 | 412 | 0.110 |
Why?
| Virus Integration | 1 | 2013 | 69 | 0.110 |
Why?
| T-Lymphocyte Subsets | 1 | 2016 | 409 | 0.110 |
Why?
| DNA Damage | 1 | 2015 | 364 | 0.100 |
Why?
| Amino Acids | 1 | 2016 | 474 | 0.100 |
Why?
| Tanzania | 2 | 2003 | 44 | 0.100 |
Why?
| Adult | 10 | 2024 | 35300 | 0.100 |
Why?
| Uganda | 2 | 2003 | 72 | 0.100 |
Why?
| Urine | 2 | 2003 | 54 | 0.100 |
Why?
| Inbreeding | 1 | 2012 | 17 | 0.100 |
Why?
| Middle Aged | 8 | 2024 | 30889 | 0.100 |
Why?
| Cell Membrane | 1 | 2016 | 720 | 0.100 |
Why?
| Down-Regulation | 3 | 2018 | 631 | 0.090 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 484 | 0.090 |
Why?
| Carcinogenesis | 2 | 2024 | 209 | 0.090 |
Why?
| Neutralization Tests | 2 | 2008 | 73 | 0.090 |
Why?
| Mutation | 3 | 2024 | 3689 | 0.090 |
Why?
| Mice, Inbred Strains | 1 | 2012 | 402 | 0.090 |
Why?
| Philippines | 3 | 2001 | 49 | 0.090 |
Why?
| DNA Primers | 3 | 2013 | 510 | 0.090 |
Why?
| B-Cell Activation Factor Receptor | 1 | 2010 | 13 | 0.090 |
Why?
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.090 |
Why?
| Protein Isoforms | 2 | 2024 | 378 | 0.090 |
Why?
| Leukemia Virus, Murine | 1 | 2010 | 17 | 0.090 |
Why?
| CD4 Antigens | 3 | 2006 | 138 | 0.090 |
Why?
| Phenylacetates | 1 | 2010 | 9 | 0.090 |
Why?
| Cytosine Deaminase | 1 | 2010 | 15 | 0.090 |
Why?
| Gene Products, gag | 1 | 2010 | 36 | 0.090 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 815 | 0.090 |
Why?
| Young Adult | 4 | 2020 | 12312 | 0.090 |
Why?
| Nitrophenols | 1 | 2010 | 38 | 0.090 |
Why?
| Plasma | 1 | 2011 | 200 | 0.080 |
Why?
| Escherichia coli | 1 | 2014 | 765 | 0.080 |
Why?
| Lentivirus | 2 | 2013 | 52 | 0.080 |
Why?
| Apoptosis | 3 | 2014 | 2435 | 0.080 |
Why?
| Sequence Analysis, RNA | 1 | 2011 | 429 | 0.080 |
Why?
| T-Lymphocytes | 3 | 2020 | 1923 | 0.080 |
Why?
| Retroelements | 2 | 2024 | 45 | 0.080 |
Why?
| Molecular Epidemiology | 2 | 2006 | 63 | 0.080 |
Why?
| Simian foamy virus | 1 | 2008 | 3 | 0.080 |
Why?
| Sequence Homology, Amino Acid | 3 | 2011 | 367 | 0.080 |
Why?
| Receptors, Antigen, B-Cell | 2 | 2020 | 126 | 0.070 |
Why?
| Phosphorylation | 2 | 2025 | 1681 | 0.070 |
Why?
| Chromosome Mapping | 1 | 2008 | 504 | 0.070 |
Why?
| Immunotherapy | 2 | 2023 | 587 | 0.070 |
Why?
| Inflammation | 1 | 2018 | 2654 | 0.070 |
Why?
| Promoter Regions, Genetic | 1 | 2011 | 1198 | 0.070 |
Why?
| Cross-Sectional Studies | 4 | 2018 | 5039 | 0.070 |
Why?
| Lentiviruses, Primate | 1 | 2006 | 13 | 0.070 |
Why?
| Genes, env | 1 | 2005 | 4 | 0.060 |
Why?
| Genes, gag | 1 | 2005 | 4 | 0.060 |
Why?
| Blotting, Western | 3 | 2010 | 1164 | 0.060 |
Why?
| Social Dominance | 1 | 2005 | 17 | 0.060 |
Why?
| Disease Transmission, Infectious | 1 | 2005 | 57 | 0.060 |
Why?
| V(D)J Recombination | 1 | 2025 | 7 | 0.060 |
Why?
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2024 | 18 | 0.060 |
Why?
| RNA Transport | 1 | 2024 | 23 | 0.060 |
Why?
| Jurkat Cells | 1 | 2024 | 131 | 0.060 |
Why?
| Poliovirus Vaccine, Oral | 1 | 2004 | 25 | 0.060 |
Why?
| Long Interspersed Nucleotide Elements | 1 | 2024 | 30 | 0.060 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 2005 | 170 | 0.050 |
Why?
| Dependovirus | 2 | 2016 | 62 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1077 | 0.050 |
Why?
| Time Factors | 1 | 2014 | 6482 | 0.050 |
Why?
| Endemic Diseases | 1 | 2003 | 30 | 0.050 |
Why?
| Retroviridae Proteins | 1 | 2003 | 11 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2018 | 1281 | 0.050 |
Why?
| Disease Outbreaks | 1 | 2006 | 341 | 0.050 |
Why?
| Mice, Transgenic | 2 | 2020 | 2071 | 0.050 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 222 | 0.050 |
Why?
| Serine-Arginine Splicing Factors | 1 | 2022 | 22 | 0.050 |
Why?
| Cytidine | 1 | 2022 | 6 | 0.050 |
Why?
| Apolipoproteins | 1 | 2022 | 38 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2002 | 1020 | 0.050 |
Why?
| Wuchereria bancrofti | 1 | 2001 | 1 | 0.050 |
Why?
| Filariasis | 1 | 2001 | 3 | 0.050 |
Why?
| DNA, Helminth | 1 | 2001 | 17 | 0.050 |
Why?
| Datasets as Topic | 1 | 2022 | 109 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2014 | 835 | 0.050 |
Why?
| World Health Organization | 1 | 2022 | 110 | 0.050 |
Why?
| Immunoblotting | 1 | 2002 | 300 | 0.050 |
Why?
| Lymphocyte Depletion | 1 | 2021 | 129 | 0.050 |
Why?
| Hemagglutination | 1 | 2020 | 8 | 0.040 |
Why?
| Macrophages | 2 | 2018 | 1460 | 0.040 |
Why?
| Antibodies | 1 | 2022 | 391 | 0.040 |
Why?
| COS Cells | 1 | 2020 | 184 | 0.040 |
Why?
| Immune Evasion | 1 | 2020 | 55 | 0.040 |
Why?
| Snails | 1 | 1999 | 34 | 0.040 |
Why?
| Gene Library | 1 | 1999 | 115 | 0.040 |
Why?
| Toll-Like Receptors | 1 | 2020 | 179 | 0.040 |
Why?
| Recombinant Fusion Proteins | 2 | 2016 | 634 | 0.040 |
Why?
| Erythroblasts | 1 | 2018 | 16 | 0.040 |
Why?
| CD4 Lymphocyte Count | 2 | 2014 | 267 | 0.040 |
Why?
| Nucleic Acid Heteroduplexes | 1 | 1998 | 8 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2003 | 1815 | 0.040 |
Why?
| Sex Work | 1 | 1998 | 20 | 0.040 |
Why?
| Interferon Regulatory Factor-7 | 1 | 2018 | 5 | 0.040 |
Why?
| Sendai virus | 1 | 2018 | 16 | 0.040 |
Why?
| Rabbits | 1 | 1999 | 758 | 0.040 |
Why?
| NF-KappaB Inhibitor alpha | 1 | 2018 | 48 | 0.040 |
Why?
| THP-1 Cells | 1 | 2018 | 22 | 0.040 |
Why?
| Enzyme Stability | 1 | 2018 | 67 | 0.040 |
Why?
| I-kappa B Kinase | 1 | 2018 | 53 | 0.040 |
Why?
| Cell Line, Transformed | 1 | 2018 | 140 | 0.040 |
Why?
| Inpatients | 1 | 2022 | 465 | 0.040 |
Why?
| Disease Progression | 2 | 2016 | 2602 | 0.040 |
Why?
| Antigenic Variation | 1 | 1997 | 9 | 0.040 |
Why?
| Antigens, Protozoan | 1 | 1997 | 22 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 416 | 0.040 |
Why?
| Plasmodium falciparum | 1 | 1997 | 29 | 0.030 |
Why?
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2017 | 12 | 0.030 |
Why?
| Malaria, Falciparum | 1 | 1997 | 26 | 0.030 |
Why?
| Palatine Tonsil | 1 | 2017 | 44 | 0.030 |
Why?
| Anti-Retroviral Agents | 1 | 2019 | 230 | 0.030 |
Why?
| Cross Reactions | 1 | 2017 | 128 | 0.030 |
Why?
| HIV Envelope Protein gp120 | 1 | 2017 | 57 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2017 | 107 | 0.030 |
Why?
| Gene Silencing | 1 | 2018 | 185 | 0.030 |
Why?
| Antigens, Surface | 1 | 1997 | 150 | 0.030 |
Why?
| DNA, Ribosomal | 1 | 2017 | 82 | 0.030 |
Why?
| Protozoan Proteins | 1 | 1997 | 75 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2017 | 82 | 0.030 |
Why?
| Interleukin-1beta | 1 | 2019 | 373 | 0.030 |
Why?
| Models, Biological | 1 | 2004 | 1691 | 0.030 |
Why?
| Peptides | 1 | 2022 | 908 | 0.030 |
Why?
| APOBEC-3G Deaminase | 1 | 2016 | 5 | 0.030 |
Why?
| Myxovirus Resistance Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2016 | 95 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2016 | 209 | 0.030 |
Why?
| Sequence Deletion | 1 | 2016 | 178 | 0.030 |
Why?
| DNA, Mitochondrial | 2 | 2008 | 188 | 0.030 |
Why?
| Imidazoles | 1 | 2016 | 226 | 0.030 |
Why?
| Cluster Analysis | 1 | 2017 | 478 | 0.030 |
Why?
| DNA, Bacterial | 1 | 2017 | 323 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2018 | 449 | 0.030 |
Why?
| Receptors, CCR7 | 1 | 2014 | 27 | 0.030 |
Why?
| Receptors, CXCR5 | 1 | 2014 | 19 | 0.030 |
Why?
| Protein Transport | 1 | 2016 | 420 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1081 | 0.030 |
Why?
| Cervix Uteri | 1 | 2014 | 50 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2017 | 519 | 0.030 |
Why?
| Viral Proteins | 1 | 2016 | 321 | 0.030 |
Why?
| Antigens, Viral | 1 | 2014 | 174 | 0.030 |
Why?
| Sexual Behavior | 1 | 1998 | 481 | 0.030 |
Why?
| Vaccines | 1 | 1999 | 393 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1355 | 0.030 |
Why?
| Caspase 1 | 1 | 2014 | 142 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 281 | 0.030 |
Why?
| Genetic Engineering | 1 | 2013 | 88 | 0.030 |
Why?
| Mucous Membrane | 1 | 2014 | 120 | 0.030 |
Why?
| Sequence Alignment | 1 | 2013 | 329 | 0.030 |
Why?
| In Vitro Techniques | 1 | 2014 | 1039 | 0.020 |
Why?
| Cytokines | 1 | 2019 | 1983 | 0.020 |
Why?
| HIV Reverse Transcriptase | 1 | 2010 | 30 | 0.020 |
Why?
| Glycosylation | 1 | 2010 | 146 | 0.020 |
Why?
| Cell Movement | 1 | 2014 | 936 | 0.020 |
Why?
| L-Selectin | 1 | 2009 | 24 | 0.020 |
Why?
| HIV Core Protein p24 | 1 | 2009 | 31 | 0.020 |
Why?
| Aged | 2 | 2017 | 21953 | 0.020 |
Why?
| Autoantibodies | 1 | 2017 | 1463 | 0.020 |
Why?
| Microbiota | 1 | 2017 | 719 | 0.020 |
Why?
| DNA Replication | 1 | 2010 | 225 | 0.020 |
Why?
| Child | 2 | 2017 | 20655 | 0.020 |
Why?
| Africa, Central | 1 | 2008 | 5 | 0.020 |
Why?
| Genetics, Microbial | 1 | 2008 | 10 | 0.020 |
Why?
| HLA-DR Antigens | 1 | 2009 | 224 | 0.020 |
Why?
| Infant, Newborn | 1 | 1999 | 5687 | 0.020 |
Why?
| Aged, 80 and over | 1 | 1999 | 7033 | 0.020 |
Why?
| Gene Products, pol | 1 | 2007 | 6 | 0.020 |
Why?
| Adolescent | 2 | 2012 | 20179 | 0.020 |
Why?
| Consensus Sequence | 1 | 2007 | 72 | 0.020 |
Why?
| Ecology | 1 | 2008 | 108 | 0.020 |
Why?
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2006 | 9 | 0.020 |
Why?
| Cameroon | 1 | 2006 | 8 | 0.020 |
Why?
| Prospective Studies | 1 | 1998 | 7036 | 0.020 |
Why?
| HIV Antibodies | 1 | 2006 | 57 | 0.020 |
Why?
| Infant | 1 | 1999 | 8914 | 0.020 |
Why?
| Child, Preschool | 1 | 1999 | 10384 | 0.010 |
Why?
| p21-Activated Kinases | 1 | 2004 | 15 | 0.010 |
Why?
| Haplotypes | 1 | 2006 | 471 | 0.010 |
Why?
| CD28 Antigens | 1 | 2004 | 48 | 0.010 |
Why?
| Africa, Western | 1 | 2004 | 17 | 0.010 |
Why?
| Risk Factors | 1 | 1998 | 9704 | 0.010 |
Why?
| Mutagenesis, Site-Directed | 1 | 2005 | 358 | 0.010 |
Why?
| Protein Binding | 1 | 2010 | 2103 | 0.010 |
Why?
| Green Fluorescent Proteins | 1 | 2005 | 380 | 0.010 |
Why?
| HeLa Cells | 1 | 2005 | 603 | 0.010 |
Why?
| Ecosystem | 1 | 2008 | 562 | 0.010 |
Why?
| Transfection | 1 | 2005 | 893 | 0.010 |
Why?
| Histocompatibility Antigens Class II | 1 | 2004 | 360 | 0.010 |
Why?
| Deoxyribonucleases, Type II Site-Specific | 1 | 2001 | 15 | 0.010 |
Why?
| Africa | 1 | 2001 | 98 | 0.010 |
Why?
| Malaria Vaccines | 1 | 1997 | 8 | 0.010 |
Why?
| DNA, Protozoan | 1 | 1997 | 26 | 0.010 |
Why?
| Point Mutation | 1 | 1997 | 223 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2004 | 3020 | 0.010 |
Why?
| Epitopes | 1 | 1997 | 466 | 0.010 |
Why?
|
|
Santiago's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|